Real Health Magazine

1 week ago | realhealthmag.com | Liz Highleyman

In a long-awaited update, the Centers for Disease Control and Prevention (CDC) issued new guidelines for HIV post-exposure prophylaxis (PEP) on May 6. The new guidance—the first revision since 2016—now includes more modern antiretrovirals taken for a month after non-occupational exposure, such as sex or injection drug use.

1 week ago | realhealthmag.com | Liz Highleyman

A single dose of the human papillomavirus (HPV) vaccine appears to provide as much protection as the currently recommended two doses for adolescents, according to findings from a nearly five-year study presented at the American Association for Cancer Research annual meeting (AACR 2025). A simpler schedule could encourage higher vaccination rates in the United States and worldwide.

1 month ago | realhealthmag.com | Liz Highleyman

Women who wear frozen or tight-fitting gloves during taxane-based chemotherapy for breast cancer are less likely to develop painful peripheral neuropathy, according to research published in JAMA Oncology. While both methods were effective, compression is more accessible and may be better tolerated than cold temperature. Cytotoxic chemotherapy is an effective treatment for many types of cancer, but the medications can harm or kill normal cells along with malignant cells, leading to side effects.

1 month ago | realhealthmag.com | Liz Highleyman

The Trump administration has rescinded hundreds of National Institutes of Health (NIH) research grants, including many that involve HIV and sexually transmitted infections (STIs). Scientists and advocates have filed a lawsuit to stop the cuts, but prospects for continued funding remain uncertain.

1 month ago | realhealthmag.com | Liz Highleyman

Broadly neutralizing antibodies (bnAbs) appeared to help keep HIV under control after stopping antiretroviral therapy and may play a role in long-term remission, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). In the RIO study, three quarters of men who received the bnAbs 3BNC117-LS and 10-1074-LS did not experience viral rebound five months after discontinuing their antiretrovirals, and a third were still in remission at 18 months.